Steatohepatitis/Metabolic Liver Disease News

In recognition of the first International NASH Day on June 12, 2018, Healio.com presents several recent reports on the diagnosis and treatment of nonalcoholic steatohepatitis, including several new drug trials that were presented at the recent International Liver Congress in Paris and Digestive Disease Week in Washington, D.C.

Albireo Pharma Inc. received a rare pediatric disease designation from the FDA for its lead product candidate A4250, an ileal bile acid transporter inhibitor designed for the treatment of progressive familial intrahepatic cholestasis, according to a company press release.

WASHINGTON — Lifestyle interventions such as diet and exercise are a critical part of prevention and treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, more so than pharmacotherapy or endoscopic interventions at this moment, according to an expert at Digestive Disease Week 2018.

WASHINGTON — Multiparametric magnetic resonance imaging identified and stratified patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis at a population level, according to a study presented at Digestive Disease Week 2018.

WASHINGTON — In this exclusive video perspective from Digestive Disease Week 2018, Steven L. Flamm, MD, chief of the Liver Program at Northwestern University Feinberg School of Medicine in Illinois, reviews some of the important clinical presentations in liver disease from the meeting.

WASHINGTON — Statins have been underused in patients with nonalcoholic fatty liver disease who had abnormal liver tests despite having appropriate indications for their use, especially among patients with concomitant diabetes, according to a study presented at Digestive Disease Week 2018.

WASHINGTON — Non-targeted metabolomics profile determined which patients with nonalcoholic fatty liver disease had comorbid coronary artery disease, according to a study presented at Digestive Disease Week 2018.

The Center for Medical Technology Policy’s Green Park Collaborative, the Forum for Collaborative Research and the Obesity Action Coalition announced the launch of its ‘coreNASH’ initiative, designed to develop a consensus on critical outcomes in nonalcoholic steatohepatitis clinical research, according to a press release.

Liver stiffness measurement through vibration-controlled transient elastography accurately distinguished between early stages of fibrosis and advanced fibrosis among patients with nonalcoholic fatty liver disease, according to recently published data.

The FDA approved avatrombopag to treat low blood platelet count among adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.